Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The object of this study was to compare the relative bioavailability (rate and extent of
absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with
that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc.
following a single oral dose in healthy adults under non-fasting conditions.